JP2013507945A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013507945A5 JP2013507945A5 JP2012534715A JP2012534715A JP2013507945A5 JP 2013507945 A5 JP2013507945 A5 JP 2013507945A5 JP 2012534715 A JP2012534715 A JP 2012534715A JP 2012534715 A JP2012534715 A JP 2012534715A JP 2013507945 A5 JP2013507945 A5 JP 2013507945A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- peripheral blood
- regulatory
- contacting
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000427 antigen Substances 0.000 claims 12
- 102000038129 antigens Human genes 0.000 claims 12
- 108091007172 antigens Proteins 0.000 claims 12
- 210000000265 Leukocytes Anatomy 0.000 claims 10
- 239000011886 peripheral blood Substances 0.000 claims 10
- 210000002901 Mesenchymal Stem Cells Anatomy 0.000 claims 9
- 210000004271 bone marrow stromal cells Anatomy 0.000 claims 9
- 210000003289 regulatory T cell Anatomy 0.000 claims 9
- 210000002950 fibroblast Anatomy 0.000 claims 8
- 238000004519 manufacturing process Methods 0.000 claims 5
- 210000004027 cells Anatomy 0.000 claims 4
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 claims 3
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims 3
- 108090000978 Interleukin-4 Proteins 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 108010002350 Interleukin-2 Proteins 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 210000000577 Adipose Tissue Anatomy 0.000 claims 1
- 101700082799 IL2RA Proteins 0.000 claims 1
- 102100002950 ISG20 Human genes 0.000 claims 1
- 101700015336 ISG20 Proteins 0.000 claims 1
- 230000001105 regulatory Effects 0.000 claims 1
Claims (15)
- 線維芽細胞集団を末梢血白血球に約2時間〜約25日間接触させることを含む、調節性T細胞の調製及び／又は産生の方法。
- 間葉系幹細胞(MSC)及び／又は線維芽細胞集団を末梢血白血球に約10〜約18日間接触させることを含む、調節性T細胞の調製及び／又は産生の方法。
- 線維芽細胞集団を、IL-2の存在下（最大約500、最大約600、最大約700、最大約800、又は最大約900IU/mlのIL-2濃度など）で末梢血白血球に接触させることを含む、調節性T細胞の調製及び／又は産生の方法。
- MSC及び／又は線維芽細胞集団を、LPS、IL-4及びGM-CSFからなる群から選択される少なくとも1種の作用物質の存在下で、末梢血白血球に接触させることを含む、調節性T細胞の調製及び／又は産生の方法。
- 選択された抗原又は抗原の群に特異的である調節性T細胞の調製及び／又は産生の方法であって、MSC及び／又は線維芽細胞集団を、LPS、IL-4及びGM-CSFからなる群から選択される少なくとも1種の作用物質の存在下で、末梢血白血球及び選択された抗原又は抗原の群に接触させることを含む、前記方法。
- 選択された抗原又は抗原の群に特異的である調節性T細胞の調製及び／又は産生の方法であって：
(a)末梢血白血球を、LPS、IL-4及びGM-CSFからなる群から選択される少なくとも1種の作用物質の存在下で、該選択された抗原又は抗原の群に接触させること、
(b)該細胞集団を、MSC及び／又は線維芽細胞集団と接触させることを含む、前記方法。 - MSC細胞集団が末梢血白血球と接触させられる、請求項２又は４〜６のいずれか一項記載の方法。
- 前記MSCが脂肪組織に由来する、請求項２又は４〜７のいずれか一項記載の方法。
- 前記MSC及び／又は線維芽細胞集団が、末梢血白血球と、約2時間〜約25日間接触させられる、請求項３〜８のいずれか一項記載の方法。
- 前記接触が約10〜約18日間実施される、請求項１又は９記載の方法。
- 前記接触が約4〜16日間実施される、請求項１又は９記載の方法。
- 前記調節性T細胞が、CD4+細胞及びCD25+細胞から選択される、請求項１〜１１のいずれか一項記載の方法。
- 前記MSC及び／又は線維芽細胞集団が、多発性硬化症関連抗原又は抗原の群の存在下において、末梢血白血球と接触させられる、請求項１〜１２のいずれか一項記載の方法によって産生された調節性T細胞の使用であって、多発性硬化症を治療するための医薬の製造のための、前記使用。
- 対象における前記選択された抗原又は抗原の群に関連する疾患及び障害の治療のための医薬の製造のための、請求項５又は６記載の方法により産生された調節性T細胞の使用。
- 前記調節性T細胞が、前記対象から得られる末梢血白血球により調製及び／又は産生されたものである、請求項１４記載の使用。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0918615.6A GB0918615D0 (en) | 2009-10-23 | 2009-10-23 | Cell populations having immunoregulatory activity, methods for the preparation and uses thereof |
| GB0918615.6 | 2009-10-23 | ||
| PCT/EP2010/066007 WO2011048222A1 (en) | 2009-10-23 | 2010-10-22 | Cell populations having immunoregulatory activity, methods for the preparation and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013507945A JP2013507945A (ja) | 2013-03-07 |
| JP2013507945A5 true JP2013507945A5 (ja) | 2013-12-12 |
Family
ID=41426608
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012534715A Pending JP2013507945A (ja) | 2009-10-23 | 2010-10-22 | 免疫調節活性を有する細胞集団、その製造方法及び使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US9969976B2 (ja) |
| EP (1) | EP2491115B1 (ja) |
| JP (1) | JP2013507945A (ja) |
| ES (1) | ES2479543T3 (ja) |
| GB (1) | GB0918615D0 (ja) |
| WO (1) | WO2011048222A1 (ja) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2710122B1 (en) * | 2011-05-19 | 2021-03-31 | TiGenix, S.A.U. | Cell populations having immunoregulatory activity, methods for the preparation and uses thereof |
| ES2434853B1 (es) * | 2012-06-12 | 2014-09-30 | Fundación Centro Nacional De Investigaciones Cardiovasculares Carlos Iii | Marcador molecular de potencia terapéutica de células madre mesenquimales humanas y sus usos |
| US11291689B2 (en) | 2015-06-03 | 2022-04-05 | Aelan Cell Technologies, Inc. | Methods and devices for the production and delivery of beneficial factors from adipose-derived stem cells |
| EP3303636B1 (en) * | 2015-06-03 | 2021-11-10 | Aelan Cell Technologies, Inc. | Companion methods for il-2-based therapies and mesenchymal stem cell-based therapies |
| AU2018375151A1 (en) * | 2017-11-29 | 2020-06-11 | Figene, Llc | Interaction of fibroblasts and immune cells for activation and uses thereof |
| EP4045065A4 (en) * | 2019-10-15 | 2023-08-30 | Figene, LLC | FIBROBLAST-BASED IMMUNOTHERAPY FOR GRAVES DISEASE |
| CN111979186B (zh) * | 2020-08-21 | 2022-04-08 | 遵义医科大学附属医院 | 一种快速高效体外扩增人间充质干细胞的方法及应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7048922B2 (en) * | 2002-05-29 | 2006-05-23 | Demao Yang | Stimulation of hematopoiesis by ex vivo activated immune cells |
| WO2005094353A2 (en) * | 2004-03-29 | 2005-10-13 | Cytomatrix, Llc | Methods for production of regulatory t cells and uses thereof |
| JP2006280307A (ja) * | 2005-04-01 | 2006-10-19 | Kyoto Univ | 制御性ｔ細胞の製造方法 |
| CN107723274B (zh) | 2005-09-23 | 2021-05-07 | 塞勒里克斯有限公司 | 具有免疫调节活性的细胞群及其分离方法和用途 |
| US8241621B2 (en) * | 2006-12-18 | 2012-08-14 | Medistem Laboratories | Stem cell mediated treg activation/expansion for therapeutic immune modulation |
| GB0820397D0 (en) * | 2008-11-07 | 2008-12-17 | Cellerix Sa | Cells, nucleic acid constructs, cells comprising said constructs and methods utilizing said cells in the treatment of diseases |
-
2009
- 2009-10-23 GB GBGB0918615.6A patent/GB0918615D0/en not_active Ceased
-
2010
- 2010-10-22 US US13/503,542 patent/US9969976B2/en active Active
- 2010-10-22 ES ES10768496.1T patent/ES2479543T3/es active Active
- 2010-10-22 JP JP2012534715A patent/JP2013507945A/ja active Pending
- 2010-10-22 EP EP10768496.1A patent/EP2491115B1/en active Active
- 2010-10-22 WO PCT/EP2010/066007 patent/WO2011048222A1/en active Application Filing
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013507945A5 (ja) | ||
| Ozaki Tan et al. | Novel applications of mesenchymal stem cell-derived exosomes for myocardial infarction therapeutics | |
| Alvites et al. | Mesenchymal stem/stromal cells and their paracrine activity—immunomodulation mechanisms and how to influence the therapeutic potential | |
| Huang et al. | Immunomodulatory mechanisms of mesenchymal stem cells and their potential clinical applications | |
| JP2015131795A5 (ja) | ||
| Fernández-Francos et al. | Mesenchymal stem cell-based therapy as an alternative to the treatment of acute respiratory distress syndrome: current evidence and future perspectives | |
| Neshat et al. | Liver disease: induction, progression, immunological mechanisms, and therapeutic interventions | |
| Orsini et al. | Defective generation and maturation of dendritic cells from monocytes in colorectal cancer patients during the course of disease | |
| JP2013504542A5 (ja) | ||
| JP2015057427A5 (ja) | ||
| MX2013004817A (es) | Enfermedad inflamatoria. | |
| Terraza-Aguirre et al. | Mechanisms behind the immunoregulatory dialogue between mesenchymal stem cells and Th17 cells | |
| AU2012274478A8 (en) | Method for amplifying NK cells | |
| Ben Khelil et al. | Harnessing antitumor CD4+ T cells for cancer immunotherapy | |
| JP5118624B2 (ja) | 新規なヒトｔ細胞集団 | |
| Wang et al. | Targeting myeloid-derived suppressor cells in cancer immunotherapy | |
| JP2013027385A5 (ja) | ||
| JP2016510727A5 (ja) | ||
| MX2007006355A (es) | Epitopes antigenos de interleucina-21, anticuerpos relacionados y su uso en el campo medico. | |
| JP2014508799A5 (ja) | ||
| Fattizzo et al. | Mesenchymal stem cells in aplastic anemia and myelodysplastic syndromes: the “Seed and Soil” crosstalk | |
| JP2014513722A5 (ja) | ||
| JP2014515258A5 (ja) | ||
| Seo et al. | Strategies to potentiate paracrine therapeutic efficacy of mesenchymal stem cells in inflammatory diseases | |
| Dai et al. | Jaw periosteal cells seeded in beta-tricalcium phosphate inhibit dendritic cell maturation |